Bli medlem
Bli medlem

Du är här


Karolinska Development AB (publ): Karolinska Development appoints Fredrik Järrsten as Deputy CEO

STOCKHOLM, SWEDEN ? 1 July 2019. Karolinska Development AB (Nasdaq
Stockholm: KDEV) announces today that Fredrik Järrsten has been appointed
as Deputy Chief Executive Officer and Chief Financial Officer. Fredrik
Järrsten joined Karolinska Development as Chief Financial Officer in 2017.

Fredrik Järrsten (b.1967), M.Sc. in Business and Economics, has more than
25 years of experience within investments and business development,
including 13 years in the Life Science sector.

?The appointment of Fredrik Järrsten as Deputy CEO is a consequence of his
deep engagement and significant contributions to the leadership of
Karolinska Development. Alongside his continuous responsibilities as CFO,
Fredrik will now be able to focus even more on strategic development and
related areas,? says Viktor Drvota, CEO, Karolinska Development AB.

For more information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail:

Fredrik Järrsten, CFO, Karolinska Development AB
Phone: +46 70 496 46 28, e-mail:


About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life
sciences investment company. The company focuses on identifying
breakthrough medical innovations that are developed by entrepreneurs and
leadership teams. The Company invests in the creation and growth of
companies that advance these assets into commercial products that are
designed to make a difference to patients' lives while providing an
attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research
institutes in the Nordic region. The Company aims to build companies around
scientists who are leaders in their fields, supported by experienced
management teams and advisers, and co-funded by specialist international
investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of nine companies
targeting opportunities in innovative treatment for life-threatening or
serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals
with a proven track record as company builders and with access to a strong
global network.

For more information:



* KD Press release Appointment Deputy CEO

Författare Hugin Nyheter

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.